Contineum Therapeutics, Inc. (CTNM)
(Delayed Data from NSDQ)
$20.77 USD
-0.23 (-1.10%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $20.60 -0.17 (-0.82%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Contineum Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 125 | 47 | -99,999 | -99,999 | -99,999 |
Receivables | 0 | 0 | NA | NA | NA |
Notes Receivable | 0 | 0 | NA | NA | NA |
Inventories | 0 | 0 | NA | NA | NA |
Other Current Assets | 3 | 1 | NA | NA | NA |
Total Current Assets | 128 | 48 | NA | NA | NA |
Net Property & Equipment | 1 | 0 | NA | NA | NA |
Investments & Advances | 0 | 0 | NA | NA | NA |
Other Non-Current Assets | 0 | 0 | NA | NA | NA |
Deferred Charges | 0 | 0 | NA | NA | NA |
Intangibles | 0 | 0 | NA | NA | NA |
Deposits & Other Assets | 1 | 0 | NA | NA | NA |
Total Assets | 130 | 51 | NA | NA | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | NA | NA | NA |
Accounts Payable | 1 | 0 | NA | NA | NA |
Current Portion Long-Term Debt | 0 | 4 | NA | NA | NA |
Current Portion Capital Leases | 0 | 0 | NA | NA | NA |
Accrued Expenses | 4 | 2 | NA | NA | NA |
Income Taxes Payable | 0 | 0 | NA | NA | NA |
Other Current Liabilities | 0 | 0 | NA | NA | NA |
Total Current Liabilities | 5 | 8 | NA | NA | NA |
Mortgages | 0 | 0 | NA | NA | NA |
Deferred Taxes/Income | 0 | 0 | NA | NA | NA |
Convertible Debt | 0 | 0 | NA | NA | NA |
Long-Term Debt | 0 | 0 | NA | NA | NA |
Non-Current Capital Leases | 0 | 0 | NA | NA | NA |
Other Non-Current Liabilities | 0 | 3 | NA | NA | NA |
Minority Interest (Liabilities) | 193 | 132 | NA | NA | NA |
Total Liabilities | 198 | 144 | NA | NA | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | NA | NA | NA |
Common Stock (Par) | 0 | 0 | NA | NA | NA |
Capital Surplus | 7 | 5 | NA | NA | NA |
Retained Earnings | -75 | -98 | NA | NA | NA |
Other Equity | 0 | 0 | NA | NA | NA |
Treasury Stock | 0 | 0 | NA | NA | NA |
Total Shareholder's Equity | -68 | -93 | NA | NA | NA |
Total Liabilities & Shareholder's Equity | 130 | 51 | NA | NA | NA |
Total Common Equity | -68 | -93 | 0 | 0 | 0 |
Shares Outstanding | 18.20 | NA | NA | NA | NA |
Book Value Per Share | -3.73 | 0.00 | 0.00 | 0.00 | 0.00 |
Fiscal Year End for Contineum Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 118 | 125 | -99,999 | -99,999 |
Receivables | NA | 0 | 0 | NA | NA |
Notes Receivable | NA | 0 | 0 | NA | NA |
Inventories | NA | 0 | 0 | NA | NA |
Other Current Assets | NA | 2 | 3 | NA | NA |
Total Current Assets | NA | 120 | 128 | NA | NA |
Net Property & Equipment | NA | 1 | 1 | NA | NA |
Investments & Advances | NA | 0 | 0 | NA | NA |
Other Non-Current Assets | NA | 0 | 0 | NA | NA |
Deferred Charges | NA | 0 | 0 | NA | NA |
Intangibles | NA | 0 | 0 | NA | NA |
Deposits & Other Assets | NA | 3 | 1 | NA | NA |
Total Assets | NA | 124 | 130 | NA | NA |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | NA | NA |
Accounts Payable | NA | 1 | 1 | NA | NA |
Current Portion Long-Term Debt | NA | 0 | 0 | NA | NA |
Current Portion Capital Leases | NA | 0 | 0 | NA | NA |
Accrued Expenses | NA | 5 | 4 | NA | NA |
Income Taxes Payable | NA | 0 | 0 | NA | NA |
Other Current Liabilities | NA | 0 | 0 | NA | NA |
Total Current Liabilities | NA | 6 | 5 | NA | NA |
Mortgages | NA | 0 | 0 | NA | NA |
Deferred Taxes/Income | NA | 0 | 0 | NA | NA |
Convertible Debt | NA | 0 | 0 | NA | NA |
Long-Term Debt | NA | 0 | 0 | NA | NA |
Non-Current Capital Leases | NA | 0 | 0 | NA | NA |
Other Non-Current Liabilities | NA | 0 | NA | NA | |
Minority Interest (Liabilities) | NA | 193 | 193 | NA | NA |
Total Liabilities | NA | 199 | 198 | NA | NA |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | NA | NA |
Common Stock (Par) | NA | 0 | 0 | NA | NA |
Capital Surplus | NA | 8 | 7 | NA | NA |
Retained Earnings | NA | -84 | -75 | NA | NA |
Other Equity | NA | 0 | 0 | NA | NA |
Treasury Stock | NA | 0 | 0 | NA | NA |
Total Shareholder's Equity | NA | -76 | -68 | NA | NA |
Total Liabilities & Shareholder's Equity | NA | 124 | 130 | NA | NA |
Total Common Equity | 0 | -76 | -68 | 0 | 0 |
Shares Outstanding | 25.70 | 2.30 | 18.20 | NA | NA |
Book Value Per Share | 0.00 | -32.88 | -3.73 | 0.00 | 0.00 |